# Drug Interactions with Antidiabetic Medications in Dogs and Cats


## Key Takeaways

- Corticosteroids are the most frequent cause of drug-induced insulin resistance and hyperglycemia in dogs and cats, necessitating a 10-25% preemptive increase in insulin dose and close monitoring with glucose curves within 5-7 days of initiation or withdrawal.
- Progestins, particularly megestrol acetate, are potent insulin antagonists in both species and carry a high risk of inducing diabetes or exacerbating existing diabetes, especially in cats.
- Topical, otic, and ophthalmic corticosteroid preparations can cause clinically significant hyperglycemia, particularly in cats, highlighting the importance of a complete drug inventory including non-systemic formulations.
- Sulfonylureas (e.g., glipizide) are effective in cats with residual beta-cell function but their efficacy is reduced by insulin-antagonizing drugs and potentiated by insulin-sensitizing agents, requiring careful monitoring for hypoglycemia when combined with protein-bound drugs.
- Concurrent diseases such as infection, inflammation, hyperthyroidism, and renal disease independently worsen glycemic control and their effects are often additive with drug interactions, requiring simultaneous management.
- Serial blood glucose curves are critical for detecting changes in insulin action within 5-7 days of adding or withdrawing interacting drugs, guiding dose adjustments by 10-25% to prevent hypoglycemia or persistent hyperglycemia.

---

Managing diabetic dogs and cats requires more than adjusting insulin dose. Many common veterinary drugs alter glucose homeostasis, insulin sensitivity, or the pharmacokinetics of antidiabetic agents, and the resulting interactions can present as unexplained hyperglycemia, recurrent hypoglycemia, or apparent insulin resistance. This article reviews the clinically relevant drug interactions that affect glycemic control in canine and feline patients, with emphasis on corticosteroids, progestins, and other insulin-antagonizing medications. It is written for practicing veterinarians who need a decision-oriented framework for anticipating, recognizing, and managing these interactions in daily practice.

The article covers the physiological basis of drug-induced glycemic disturbance, the major classes of interacting drugs, species-specific considerations for dogs and cats, and practical monitoring and adjustment strategies. The scope includes interactions that raise or lower blood glucose, those that alter insulin action or secretion, and those that affect the absorption or metabolism of oral antidiabetic agents. Excluded are interactions that primarily affect non-glycemic outcomes, such as cardiovascular or renal effects, except where they influence insulin dosing decisions.

## At a Glance

| Parameter | Clinical Relevance |
|---|---|
| Corticosteroids | Most common cause of drug-induced insulin resistance, dose-dependent hyperglycemia in dogs and cats |
| Progestins | Diabetogenic in both species, megestrol acetate carries high risk in cats |
| Glucocorticoid route | Topical, otic, and ophthalmic preparations can cause clinically significant hyperglycemia |
| Insulin antagonism | Growth hormone, glucagon, epinephrine, cortisol all counter-regulatory |
| Sulfonylureas in cats | Glipizide efficacy limited by requirement for residual beta-cell function |
| Monitoring interval | Recheck glucose curves within 5 to 7 days after adding or withdrawing an interacting drug |
| Insulin dose adjustment | Increase by 10 to 25 percent when corticosteroids are added, reduce when steroids are tapered |
| Concurrent disease | Infection, inflammation, hyperthyroidism, and renal disease independently worsen glycemic control |

## Physiology of Drug-Induced Glycemic Disturbance

Glucose homeostasis depends on the balance between insulin secretion, insulin sensitivity, hepatic glucose output, and peripheral glucose utilization. Counter-regulatory hormones, including cortisol, glucagon, epinephrine, and growth hormone, oppose insulin action and raise blood glucose. Drugs that mimic or stimulate these hormones, or that interfere with insulin secretion or signaling, shift this balance toward hyperglycemia. Conversely, drugs that enhance insulin sensitivity, suppress hepatic gluconeogenesis, or potentiate insulin secretion can precipitate hypoglycemia, particularly in patients already receiving insulin or sulfonylureas.

The gut microbiota also modulates host glucose metabolism and the response to antidiabetic drugs. Metformin, alpha-glucosidase inhibitors, and other agents alter intestinal bacterial composition, and these changes may contribute to their therapeutic effects. The clinical relevance of microbiota-mediated drug interactions in dogs and cats remains poorly defined, but the recognition that antidiabetic drugs and gut bacteria interact through multiple pathways is established in the human and animal literature. This background matters for the veterinary clinician because it explains why the glycemic response to a drug change can be delayed, variable, and difficult to predict from pharmacokinetic considerations alone.

## Corticosteroids

Glucocorticoids are the most frequently encountered diabetogenic drugs in small animal practice. They increase hepatic gluconeogenesis, antagonize insulin at the receptor and post-receptor level, and impair peripheral glucose uptake. The magnitude of the effect depends on the drug, dose, route, and duration of therapy. Prednisolone and dexamethasone are the most commonly implicated systemic agents, but topical, otic, and ophthalmic preparations can also produce clinically significant hyperglycemia, especially in cats, which are particularly sensitive to glucocorticoid-induced insulin resistance.

In a diabetic patient, adding a glucocorticoid typically raises insulin requirements within 24 to 72 hours. The increase can be substantial, often 25 to 50 percent or more, and may require repeated dose escalation over days to weeks. When the glucocorticoid is tapered or discontinued, insulin requirements fall, and failure to reduce the insulin dose can cause severe hypoglycemia. The same principle applies to cats receiving glipizide or other sulfonylureas, where glucocorticoid-induced insulin resistance can overwhelm the limited insulin secretory capacity that remains.

Clinical guidance from the human literature, which is directly applicable to veterinary patients, states that glucocorticoid administration is not contraindicated in diabetic subjects but usually necessitates pharmacotherapeutic adjustment. Blood glucose monitoring should be intensified before, during, and after glucocorticoid therapy. For a diabetic dog or cat starting a short course of prednisolone, a reasonable approach is to increase the insulin dose by 10 to 25 percent preemptively and then adjust based on serial glucose curves. For long-term glucocorticoid therapy, the insulin dose should be titrated against twice-daily glucose measurements and clinical signs.

## Progestins and Other Insulin Antagonists

Progestins, particularly megestrol acetate, are potent insulin antagonists in both dogs and cats. They induce growth hormone secretion, which in turn causes insulin resistance and can lead to overt diabetes mellitus. Cats treated with megestrol acetate for behavioral or dermatologic conditions are at high risk for developing diabetes, and the effect can persist for weeks after drug withdrawal. In a diabetic cat, megestrol acetate should be avoided unless no alternative exists, and if it is used, insulin requirements will rise substantially.

Other drugs with insulin-antagonizing effects include growth hormone preparations, diazoxide, and certain beta-agonists. Diazoxide, used occasionally for insulinoma or hypoglycemia, inhibits insulin secretion and raises blood glucose by design. Glucagon, used in emergency hypoglycemia treatment, is a short-acting counter-regulatory hormone. Thiazide diuretics and beta-blockers have mild hyperglycemic effects in humans, but their clinical impact in diabetic dogs and cats is usually small unless used at high doses or in combination with other diabetogenic drugs.

## Sulfonylureas and Oral Antidiabetic Agents

Sulfonylureas such as glipizide are used primarily in cats with type 2 diabetes mellitus, where residual beta-cell function is present. These drugs stimulate insulin secretion from pancreatic beta-cells, and their efficacy depends on the presence of functional beta-cells. Any drug that impairs insulin secretion, such as diazoxide, or that increases insulin resistance, such as glucocorticoids, will reduce the effectiveness of sulfonylureas. Conversely, drugs that enhance insulin sensitivity, such as thiazolidinediones, can potentiate the hypoglycemic effect of sulfonylureas, although these agents are rarely used in veterinary practice.

Drug interactions that induce hypoglycemia in diabetic patients affect mostly those taking sulfonylureas. Nonsteroidal anti-inflammatory drugs, sulfonamides, and certain antifungals can displace sulfonylureas from protein binding sites or inhibit their metabolism, increasing the risk of hypoglycemia. The clinical significance of these interactions in cats is uncertain, but caution is warranted when adding any highly protein-bound drug to a cat receiving glipizide. Blood glucose should be monitored more frequently during the first week of combination therapy.

## Monitoring and Adjustment Framework

When an interacting drug is added, changed, or withdrawn, the glycemic response should be assessed within 5 to 7 days. A full glucose curve, with measurements every 2 to 4 hours over 12 to 24 hours, is the most reliable method for detecting changes in insulin action. For patients on insulin, the dose should be adjusted in increments of 10 to 25 percent based on the curve results. For patients on oral antidiabetic agents, the drug may need to be discontinued or supplemented with insulin if glycemic control deteriorates.

Concurrent disease states, including infection, inflammation, hyperthyroidism, and chronic kidney disease, independently worsen glycemic control and should be identified and treated before attributing poor control to a drug interaction. The interaction between disease and drugs is often additive, and the clinician should address both factors simultaneously. When the interacting drug is withdrawn, insulin requirements may fall rapidly, and the dose should be reduced preemptively to avoid hypoglycemia.

## Structured Assessment of the Diabetic Patient on Concurrent Medications

The first step in managing a suspected drug interaction is to determine whether the interaction is real, clinically relevant, and dose dependent. Begin by compiling a complete medication list, including topical preparations, otic drops, ophthalmic solutions, and any compounded products. Owners frequently omit these. Ask specifically about glucocorticoid-containing ear or eye medications, progestin implants or injections, and any historical or current hormone therapy.

Next, establish the temporal relationship. A change in insulin requirement that coincides with starting a new medication, or with a dose change of an existing medication, points toward a drug interaction. If the glycemic disturbance precedes the medication change, investigate other causes first: dietary indiscretion, infection, pancreatitis, or progression of the underlying endocrinopathy.

Quantify the disturbance. Serial blood glucose curves are more informative than isolated spot checks. In cats, a single stress hyperglycemia reading can exceed 300 mg/dL and does not distinguish between poor regulation and drug effect. A home blood glucose curve performed over 8 to 12 hours, or a continuous glucose monitor trace, provides the data needed to adjust insulin rationally. In dogs, the same principle applies, though stress hyperglycemia is less pronounced.

Document the direction and magnitude of change. A dog receiving prednisone at anti-inflammatory doses may require a 25% to 50% increase in insulin dose, while immunosuppressive doses can double or triple the requirement. Cats receiving progestin therapy for behavioral or dermatologic conditions may become frankly insulin resistant within days. Record the insulin dose, the glucose curve, and the concurrent drug dose at each reassessment so that trends become visible.

## Decision Points for Continuing or Modifying the Interacting Drug

The decision to continue, reduce, or stop the interacting drug depends on three questions. First, is the medication essential? A short course of prednisone for a severe allergic reaction may be unavoidable, whereas a progestin used for estrus suppression in a diabetic bitch should be discontinued and replaced with a non-hormonal alternative. Second, can the dose be reduced? Glucocorticoid effects on glycemia are dose dependent, and the lowest effective dose may preserve acceptable control. Third, can the medication be changed to a less diabetogenic alternative? Budesonide has lower systemic bioavailability than prednisone in dogs and may cause less hyperglycemia, though it is not without systemic effects.

When the interacting drug must continue, adjust insulin proactively instead of reactively. If the patient is starting a course of corticosteroids, increase the insulin dose before severe hyperglycemia develops, or at minimum schedule a glucose curve within 3 to 5 days. Waiting for clinical signs of polyuria and polydipsia to appear delays correction by days. In cats, consider switching from a twice-daily intermediate insulin to a longer-acting preparation if the duration of insulin effect is inadequate during glucocorticoid therapy.

When the interacting drug is stopped, reduce the insulin dose in anticipation of improved sensitivity. A common failure mode is continuing the elevated insulin dose after corticosteroid withdrawal, producing hypoglycemia within 24 to 72 hours. Advise owners to monitor for lethargy, weakness, and ataxia, and provide clear instructions for emergency glucose administration. Schedule a follow-up glucose curve within 5 to 7 days of stopping the interacting drug.

## Monitoring Parameters and Their Interpretation

| Parameter | What It Detects | Frequency | Action Threshold |
|-----------|----------------|-----------|------------------|
| Serial blood glucose curve | Duration of insulin effect, peak and nadir timing | Every 3 to 7 days during dose changes | Nadir below 80 mg/dL in dogs, below 70 mg/dL in cats |
| Fructosamine | Average glycemia over prior 2 to 3 weeks | Every 2 to 4 weeks | Rising trend despite stable insulin dose suggests insulin resistance |
| Continuous glucose monitor | Nocturnal hypoglycemia, postprandial excursions | 7 to 14 day wear periods | Time below range exceeding 4% of readings |
| Body weight | Caloric intake, insulin sensitivity trend | Weekly | Weight gain with persistent hyperglycemia suggests overfeeding |
| Clinical signs score | Polydipsia, polyuria, appetite, activity | Daily by owner | Any deterioration warrants earlier glucose curve |
| Urine glucose and ketones | Glucosuria, ketonuria | Daily during instability | Ketones present requires immediate veterinary assessment |

Fructosamine is useful for confirming overall control but lags behind acute changes by 2 to 3 weeks. It cannot detect day-to-day instability and should not be used as the sole monitoring tool during an interaction. Continuous glucose monitoring provides the richest dataset, particularly for detecting hypoglycemia during the transition off an interacting drug, but requires owner compliance and appropriate device placement. The [MSD Veterinary Manual](https://www.msdvetmanual.com/) provides species-specific reference intervals and monitoring guidance for diabetic dogs and cats.

## Species Differences in Interaction Management

Dogs and cats differ in their typical responses to insulin-antagonizing drugs. Dogs are more commonly affected by glucocorticoid-induced insulin resistance because corticosteroid use is frequent in canine dermatology and immunology. Cats are more sensitive to progestin effects, and the association between progestin therapy and diabetes mellitus in cats is well recognized. Feline remission is possible after resolution of the antagonizing factor, particularly if the diabetes is of short duration and the cat is managed with tight glycemic control during the interaction.

Insulin type selection also differs. Dogs are typically managed with intermediate or long-acting insulins, and dose adjustments follow the glucose curve. Cats may respond better to longer-acting preparations, and some cats achieve remission with tight control, making aggressive dose reduction after removal of the antagonizing drug particularly important. In both species, the choice of insulin preparation should be based on the duration of action observed on the glucose curve, not on a fixed protocol.

## Documentation and Communication

Record the interacting drug, its dose, route, and indication in the medical record at every visit. Note the anticipated effect on glycemia and the planned monitoring schedule. When an interaction is identified, document the glucose data that established the relationship, the dose adjustments made, and the response to those adjustments. This creates a clear record for future clinicians and supports rational decision making if the same drug is prescribed again.

Communicate the interaction to the owner in practical terms. Explain that the insulin dose may need to change while the other medication is being given and that blood glucose monitoring is the tool that guides those changes. Provide written instructions for recognizing hypoglycemia and for contacting the clinic. The [FDA Center for Veterinary Medicine](https://www.fda.gov/animal-veterinary) maintains adverse event reporting pathways that can be used when an unexpected or severe drug interaction is observed, and reporting contributes to the broader understanding of these effects in veterinary patients.

## Managing Refractory Hyperglycemia During Interactions

When hyperglycemia persists despite appropriate insulin dose escalation, reassess the assumptions. Confirm that the insulin product has been stored correctly and that the owner is administering the full dose. Check the injection technique, including needle size and site rotation. Verify that the insulin concentration matches the syringe markings, particularly with U-40 and U-100 products. These practical failures are more common than true pharmacodynamic resistance.

If the interacting drug is a glucocorticoid, consider whether the dose has been increased without your knowledge, or whether the owner has applied a topical product containing the same drug class. If the patient is receiving multiple diabetogenic drugs, the combined effect may be greater than the sum of individual effects. In this situation, prioritize which drug can be safely withdrawn first and manage the remaining drug with dose adjustment.

When glycemic control cannot be achieved despite maximal adjustment, reconsider the diagnosis. Concurrent acromegaly in cats, hyperadrenocorticism in dogs, or exocrine pancreatic insufficiency can all present as apparent insulin resistance. The presence of an interacting drug does not exclude these conditions, and diagnostic testing should proceed if the response to dose adjustment is inadequate. The [AVMA practice resources](https://www.avma.org/resources-tools) provide guidance on referral pathways and specialty consultation when cases exceed the capacity of primary care practice.

## Recognized Complications and Failure Modes

The principal failure modes in managing diabetic patients on interacting drugs are persistent hyperglycemia, hypoglycemia, and apparent insulin resistance. Persistent hyperglycemia is the most common and is usually detected through serial glucose curves, fructosamine measurements, or continuous glucose monitoring. When hyperglycemia persists beyond 48 to 72 hours after a dose increase, the clinician should suspect ongoing antagonism instead of inadequate dosing. Hypoglycemia occurs most often when the interacting drug is withdrawn without corresponding reduction in insulin or sulfonylurea dose, or when an insulin-sensitizing agent is added to a stable regimen. Apparent insulin resistance, defined as failure to achieve target glycemia despite escalating doses, should trigger a structured search for an unrecognized interacting drug, concurrent disease, or owner administration error.

Early detection depends on disciplined monitoring. A glucose curve performed 7 to 10 days after starting or stopping a potentially interacting drug identifies trends before clinical signs appear. Fructosamine reflects control over the preceding 2 to 3 weeks and is useful when curve data are unreliable. Owners should be asked specifically about topical medications, compounded products, and supplements, since these are frequently omitted from medication histories. The [FDA Center for Veterinary Medicine](https://www.fda.gov/animal-veterinary) maintains labeling and adverse event resources that can clarify whether a product contains a known insulin antagonist.

## Common Clinical Errors and Corrective Actions

A frequent error is attributing worsening glycemia solely to the diabetic state while overlooking a newly prescribed glucocorticoid or progestin. The corrective action is a complete drug inventory at every recheck, including ophthalmic and dermatologic preparations. Another error is adjusting insulin dose on the basis of a single glucose reading instead of a curve, this leads to oscillation between hyperglycemia and hypoglycemia. The corrective action is to obtain at least 6 to 8 readings over 12 to 24 hours before changing dose.

A third error is failing to anticipate the resolution of drug-induced antagonism. When a glucocorticoid course ends, insulin requirements may fall within days, and the pre-existing dose can cause hypoglycemia. The corrective action is to reduce insulin by 10 to 25 percent when the interacting drug is discontinued and to re-evaluate within 5 to 7 days. A fourth error involves sulfonylureas in cats: adding a second oral agent or insulin without reassessing the original drug's contribution can produce additive hypoglycemia. The corrective action is to review the entire antidiabetic regimen before any addition, as outlined in [drug interaction reviews for diabetic patients](https://pubmed.ncbi.nlm.nih.gov/7667806/).

## Limitations of the Evidence and Areas of Disagreement

The veterinary literature on antidiabetic drug interactions is largely extrapolated from human medicine and small case series. Controlled interaction studies in dogs and cats are scarce, and most dosing recommendations derive from clinical experience instead of prospective trials. Expert opinion differs on several points. Whether exogenous insulin requirements increase predictably with a given glucocorticoid dose is contested, some clinicians expect a 30 to 50 percent increase, while others prefer to titrate entirely by response. The role of gut microbiota in modulating antidiabetic drug efficacy is recognized in human type 2 diabetes research, but its clinical relevance in dogs and cats remains unclear, as [reviews of gut microbiota and antidiabetic drug action](https://pubmed.ncbi.nlm.nih.gov/30891151/) acknowledge that a clear overview has not yet formed. The use of thiazolidinediones in veterinary patients is limited by historical safety concerns and species differences in metabolism, and current guidance relies on older human data, such as [assessments of troglitazone pharmacology and interactions](https://pubmed.ncbi.nlm.nih.gov/9533065/).

## Troubleshooting Table

| Observation | Likely Cause | Discriminating Check |
|---|---|---|
| Glucose curve 20 to 30 percent above target for 7 days | Unrecognized glucocorticoid or progestin exposure | Full drug inventory including topical and compounded products |
| Hypoglycemia within 3 days of stopping an interacting drug | Insulin dose not reduced when antagonism resolved | Review dose change history, reduce dose and recheck in 5 to 7 days |
| Fructosamine elevated but glucose curve near normal | Stress hyperglycemia or intermittent poor control | Repeat curve at home, correlate with owner log |
| No response to repeated insulin dose increases | Insulin resistance from concurrent disease or drug | Check fructosamine, urine culture, thyroid status, review all medications |
| Erratic glucose readings with no pattern | Owner administration error or insulin storage problem | Observe owner technique, verify product handling and expiry |

## Referral, Consultation, and Reporting

Referral to an internal medicine specialist is warranted when glycemic control cannot be achieved despite systematic adjustment over 4 to 6 weeks, when hypoglycemia is recurrent or severe, or when the interacting drug cannot be discontinued and no alternative exists. Specialist consultation is also appropriate for diabetic ketoacidosis, for cats requiring complex insulin regimens, and for cases where an insulinoma or other endocrine comorbidity is suspected. Laboratory involvement is indicated for fructosamine measurement, glucose curve interpretation, and assessment of concurrent conditions such as pancreatitis or urinary tract infection.

Regulatory reporting applies when an adverse drug event is suspected, particularly for approved veterinary products. The [FDA Center for Veterinary Medicine](https://www.fda.gov/animal-veterinary) accepts adverse event reports for animal drugs, and practitioners should report unexpected interactions, lack of efficacy, or suspected product defects. For antimicrobial stewardship concerns that arise during management of diabetic infections, the [AVMA antimicrobial stewardship resources](https://www.avma.org/resources-tools/one-health/antimicrobial-use-and-antimicrobial-resistance) provide guidance on judicious use. International practitioners should consult [WOAH terrestrial animal health standards](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/) where trade or notifiable disease considerations apply, though these rarely affect routine diabetic management.

## Frequently Asked Questions

### How should I adjust insulin dosing when a diabetic dog requires a short course of oral corticosteroids?

A short corticosteroid course predictably raises insulin requirements, often within 24 to 48 hours. Anticipate a 25 to 50 percent increase in total daily insulin dose before starting therapy, then re-evaluate glucose curves every 3 to 5 days. If the steroid course lasts less than 7 days, consider maintaining the higher dose until 48 hours after the last steroid dose, then taper insulin back toward the original dose. If the dog develops polyuria, polydipsia, or ketonuria despite dose escalation, reassess instead of continuing to push insulin upward. Consult a current veterinary formulary for species-specific insulin products and monitoring intervals, and document the steroid exposure clearly in the record because it explains transient insulin resistance [MSD Veterinary Manual](https://www.msdvetmanual.com/).

### What monitoring approach is practical when a cat on glipizide develops hyperglycemia from concurrent progestin therapy?

Progestin-induced insulin antagonism often overwhelms glipizide's capacity to lower glucose. Measure blood glucose and fructosamine at baseline, then weekly for the first month of combined therapy. If glucose remains above 250 mg/dL or fructosamine rises beyond the reference interval, glipizide is unlikely to regain control and transition to insulin is usually required. Do not simply increase glipizide dose without confirming that the progestin course has a defined endpoint. If the progestin is long-acting, plan for permanent insulin therapy. Recheck fructosamine 2 to 3 weeks after any dose change because it reflects the preceding 2-week average instead of a single reading [MSD Veterinary Manual](https://www.msdvetmanual.com/).

### How do I manage a diabetic dog when only once-daily insulin is affordable for the owner?

Once-daily insulin is workable for some dogs, particularly those with mild hyperglycemia and no history of ketoacidosis. Choose a longer-acting insulin preparation and measure a 12-hour glucose curve to confirm that the dose provides adequate coverage without hypoglycemia late in the day. If the curve shows glucose rising above 300 mg/dL before the next injection, discuss with the owner whether twice-daily dosing is truly unaffordable or whether a different insulin product at the same total daily cost would permit split dosing. Document the financial constraint and the monitoring plan in the record. Reassess at each visit because affordability can change, and a dog that initially stabilizes on once-daily dosing may later require twice-daily therapy as the disease progresses [MSD Veterinary Manual](https://www.msdvetmanual.com/).

### What should I record when an interacting drug is added to a diabetic patient's regimen?

Record the indication for the interacting drug, the expected direction and magnitude of glycemic effect, the date of initiation, and the baseline glucose and fructosamine values. Note the planned monitoring schedule and the threshold at which you will alter insulin or oral antidiabetic dosing. Each recheck should document glucose curve results, insulin dose, body weight, and any episodes of hypoglycemia or hyperglycemia. If the interacting drug is discontinued, record the date and the subsequent insulin adjustments. This documentation supports later clinical decisions and provides a defensible record if another clinician assumes care of the case. Clear records also help identify patterns when a patient presents with unexplained glycemic instability [AVMA practice resources](https://www.avma.org/resources-tools).

### How do I explain corticosteroid-induced hyperglycemia to a client whose diabetic pet needs anti-inflammatory therapy?

Explain that corticosteroids raise blood glucose by reducing the body's response to insulin, so the pet will likely need more insulin while taking the medication. Frame this as an expected and manageable change instead of a treatment failure. Tell the client to watch for increased thirst, urination, and appetite, and to report any vomiting, lethargy, or weakness immediately. Clarify that the insulin dose will be adjusted based on glucose measurements, not on how the pet appears. Advise the client not to change insulin doses on their own. Provide written instructions for when to call the clinic and schedule the first recheck before the steroid course begins. This preparation reduces client anxiety and improves compliance with monitoring [AVMA practice resources](https://www.avma.org/resources-tools).

### When should I refer a diabetic patient with a drug interaction to a specialist?

Refer when the patient remains hyperglycemic despite appropriate dose escalation, develops recurrent hypoglycemia while an interacting drug is being tapered, or requires a drug combination you cannot monitor adequately in your practice setting. Referral is also appropriate when the interacting drug is essential for a concurrent disease and you have exhausted standard adjustment protocols without achieving glycemic targets. If the patient develops ketoacidosis, unstable retinopathy, or concurrent endocrine disease such as hyperadrenocorticism, specialist input is warranted before further medical management. Prepare a summary of glucose curves, insulin doses, drug exposures, and monitoring results for the referral. If referral is declined by the owner, document the discussion and continue structured monitoring with clear thresholds for emergency presentation [MSD Veterinary Manual](https://www.msdvetmanual.com/).

## Related Clinical & Scientific Guides

* [Veterinary Formulary Essentials: Navigating Drug References](/knowledge/veterinary-medicine/clinical-pharmacology/veterinary-formulary-essentials-navigating-drug-references)
* [Drug Interactions with Antiepileptic Drugs in Veterinary Patients: Managing Polypharmacy](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-antiepileptic-veterinary)
* [Drug Interactions with Corticosteroids in Veterinary Patients: A Comprehensive Review](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-corticosteroids-veterinary-comprehensive)


## References and Further Reading

- [Crosstalk between gut microbiota and antidiabetic drug action.](https://pubmed.ncbi.nlm.nih.gov/30891151/). 2019.
- [Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus.](https://pubmed.ncbi.nlm.nih.gov/9533065/). 1998.
- [[Drug interactions in diabetic patients].](https://pubmed.ncbi.nlm.nih.gov/7667806/). 1995.
- [L-Quebrachitol Enhances Sedative Effect of Diazepam Through GABAergic Pathway: Animal and Computational Studies.](https://pubmed.ncbi.nlm.nih.gov/41527489/). 2026.
- [FDA Center for Veterinary Medicine: Animal Drug Information](https://www.fda.gov/animal-veterinary). FDA CVM.
- [AVMA Antimicrobial Use and Stewardship](https://www.avma.org/resources-tools/one-health/antimicrobial-use-and-antimicrobial-resistance). American Veterinary Medical Association.
- [MSD Veterinary Manual, Professional Edition](https://www.msdvetmanual.com/). MSD Veterinary Manual.
- [American Veterinary Medical Association Practice Resources](https://www.avma.org/resources-tools). American Veterinary Medical Association.
- [WOAH Terrestrial Animal Health Code](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/). WOAH.

## Related Articles

- [Drug Interactions with Antihypertensive Medications in Veterinary Patients](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-antihypertensive-medications-veterinary)
- [Drug Interactions with Anticonvulsant Medications in Veterinary Patients: Phenobarbital, Potassium Bromide, and Levetiracetam](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-anticonvulsant-medications-veterinary)
- [Drug Interactions with Cardiovascular Medications in Veterinary Patients: Beta-Blockers, ACE Inhibitors, and More](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-cardiovascular-veterinary)
- [Drug Interactions in Veterinary Oncology: Managing Polypharmacy](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-veterinary-oncology-managing-polypharmacy)
- [Drug Interactions with Antacids and Gastroprotectants in Veterinary Patients](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-antacids-veterinary)

> This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.